parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	group enriched in oligodendrocytes (335 nCPM)	1.00
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 102	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 5506

NKX6-2 in oligodendrocytes, braak+0.04 (p 0.910) → +0.69 (p 0.041)receipt 5515
NKX6-2 in dopamine neurons, braak+0.36 (p 0.344) → -0.72 (p 0.028)receipt 5516

receipt 5516: NKX6-2 in dopamine neurons, braak

power: full sample +0.01 (p 0.983, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.01 (p 0.983, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.01 (p 0.983, n 18). could be the mix.
skeptic: leave-one-out range -0.13 to +0.09, sign flips 5; without severely affected donors +0.01 (p 0.983, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NKX6-2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5515: NKX6-2 in oligodendrocytes, braak

power: full sample +0.22 (p 0.389, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.23 (p 0.351, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.23 (p 0.369, n 18). could be the mix.
skeptic: leave-one-out range +0.13 to +0.35, sign flips 0; without severely affected donors +0.22 (p 0.389, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NKX6-2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts